About NeuroPace, Inc.
https://www.neuropace.comNeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source.
CEO
Joel D. Becker
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 58
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
POLAR CAPITAL HOLDINGS PLC
Shares:3.1M
Value:$51.89M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:2.96M
Value:$49.55M
ORBIMED ADVISORS LLC
Shares:2.61M
Value:$43.79M
Summary
Showing Top 3 of 91
About NeuroPace, Inc.
https://www.neuropace.comNeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.35M ▲ | $23.77M ▼ | $-3.5M ▲ | -12.78% ▲ | $-0.11 ▲ | $-2.46M ▲ |
| Q2-2025 | $23.52M ▲ | $24.96M ▲ | $-8.65M ▼ | -36.78% ▼ | $-0.26 ▼ | $-6.12M ▼ |
| Q1-2025 | $22.52M ▲ | $22.49M ▲ | $-6.59M ▼ | -29.25% ▼ | $-0.21 ▼ | $-3.97M ▼ |
| Q4-2024 | $21.47M ▲ | $19.84M ▲ | $-5.25M ▲ | -24.46% ▲ | $-0.18 ▲ | $-2.61M ▲ |
| Q3-2024 | $21.06M | $19.66M | $-5.45M | -25.89% | $-0.19 | $-2.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $60.01M ▼ | $107.25M ▲ | $88.74M ▲ | $18.52M ▼ |
| Q2-2025 | $62.14M ▼ | $106.11M ▼ | $86.68M ▲ | $19.44M ▼ |
| Q1-2025 | $66.26M ▲ | $110.2M ▲ | $85.94M ▼ | $24.27M ▲ |
| Q4-2024 | $52.76M ▼ | $94.65M ▼ | $86.63M ▲ | $8.01M ▼ |
| Q3-2024 | $56.83M | $96.3M | $86.48M | $9.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.5M ▲ | $-1.94M ▲ | $-30K ▲ | $-235K ▲ | $-2.21M ▲ | $-1.97M ▲ |
| Q2-2025 | $-8.65M ▼ | $-2.09M ▲ | $-168K ▼ | $-1.91M ▼ | $-4.16M ▼ | $-2.25M ▲ |
| Q1-2025 | $-6.59M ▼ | $-7.48M ▼ | $-37K ▼ | $21.11M ▲ | $13.59M ▲ | $-7.52M ▼ |
| Q4-2024 | $-5.25M ▲ | $-4.8M ▼ | $1.96M ▲ | $848K ▼ | $-1.99M ▼ | $-4.84M ▼ |
| Q3-2024 | $-5.45M | $-1.72M | $1.4M | $2.9M | $2.57M | $-1.82M |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 |
|---|---|---|
 NonUS | $0 ▲ | $0 ▲ |
CEO
Joel D. Becker
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 58
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
POLAR CAPITAL HOLDINGS PLC
Shares:3.1M
Value:$51.89M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:2.96M
Value:$49.55M
ORBIMED ADVISORS LLC
Shares:2.61M
Value:$43.79M
Summary
Showing Top 3 of 91